While general COPD treatment patterns are consistent across the emerging markets compared to the US, some key distinctions between countries have been identified, which impact market potential and growth opportunities. In particular, regulations in the emerging markets play a considerable role in the availability and spectrum of COPD treatments compared to the US.
Scope of this research
- Insight into COPD in emerging markets based on a survey of 300 physicians in Brazil, India, China, and the US
- Robust and comparable epidemiology estimates of the current COPD patient population in Brazil, India, China and the US
- Overview of treatment patterns by severity, and patient segmentation by GOLD guidelines as well as by exacerbation rates, age and smoking status
- Assessment of commercial attractiveness of the emerging markets based on current COPD drug usage, regulations and intellectual property rights
Research and analysis highlights
Survey respondents believe less than half of COPD patients are diagnosed. The perceived diagnosis rate was found to be the highest in the US, 45.5%, and the lowest in Brazil, 29.8%. Low diagnosis was attributed mainly to lack of patient awareness, such that with increased attention to the disease, patient potential could increase considerably.
A greater share of physician reported mild and moderate patients was found in the emerging markets versus the US. In Brazil 32.8% of patients are considered mild, over double the rate in the US (15.8%). These results suggest that, with spirometry lacking, subjectivity leads to different classifications, despite claims of GOLD criteria adherence.
Emerging markets respondents have a more fragmented choice of preferred COPD products than the US. In India, most respondents prefer products from local company Cipla. Patent laws in the emerging markets have allowed generic availability before the US, but changing regulations are expected to impact the situation in the future.
Key reasons to purchase this research
- Target physicians more effectively, through an understanding of prescribing behavior and influences
- Understand treatment outcomes and challenges and their relative importance to prescribing physicians
- Validate new product forecasting based on diagnosis and treatment rates, and interest in novel products